These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 28575536)

  • 1. Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach.
    Webers C; Essers I; van Tubergen A; Braun J; Heldmann F; Baraliakos X; Boonen A
    Arthritis Care Res (Hoboken); 2018 Apr; 70(4):608-616. PubMed ID: 28575536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
    Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
    Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N; Lee YC; Shah N; Harrison DJ
    Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment with golimumab or infliximab reduces health resource utilization and increases work productivity in patients with ankylosing spondylitis in the QUO-VADIS study, a large, prospective real-life cohort.
    Claudepierre P; Van den Bosch F; Sarzi-Puttini P; Vastesaeger N; Govoni M; Kachroo S
    Int J Rheum Dis; 2019 Jun; 22(6):995-1001. PubMed ID: 30989813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. User Fees in General Practice: Willingness to Pay and Potential Substitution Patterns-Results from a Danish GP Patient Survey.
    Kronborg C; Pedersen LB; Fournaise A; Kronborg CN
    Appl Health Econ Health Policy; 2017 Oct; 15(5):615-624. PubMed ID: 28364368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab.
    Heldmann F; Brandt J; van der Horst-Bruinsma IE; Landewe R; Sieper J; Burmester GR; van den Bosch F; de Vlam K; Geusens P; Gaston H; Schewe S; Appelboom T; Emery P; Dougados M; Leirisalo-Repo M; Breban M; Listing J; Braun J
    Clin Exp Rheumatol; 2011; 29(4):672-80. PubMed ID: 21906431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
    Bonafede M; Joseph GJ; Princic N; Harrison DJ
    J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF-alpha inhibitors for ankylosing spondylitis.
    Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD005468. PubMed ID: 25887212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Willingness to pay for a cure in patients with chronic gout.
    Khanna D; Ahmed M; Yontz D; Ginsburg SS; Tsevat J
    Med Decis Making; 2008; 28(4):606-13. PubMed ID: 18349436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
    Boonen A; van der Heijde D; Severens JL; Boendermaker A; Landewé R; Braun J; Brandt J; Sieper J; van der Linden S
    Ann Rheum Dis; 2006 Feb; 65(2):201-8. PubMed ID: 16014677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness of patients with ankylosing spondylitis to pay for inpatient treatment is influenced by the treatment environment and expectations of improvement.
    Boonen A; Severens JL; van Tubergen A; Landewé R; Bonsel G; van der Heijde D; van der Linden S
    Ann Rheum Dis; 2005 Nov; 64(11):1650-2. PubMed ID: 16227417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of two therapeutic regimens of infliximab in ankylosing spondylitis: economic evaluation within a randomised controlled trial.
    Fautrel B; Benhamou M; Breban M; Roy C; Lenoir C; Trape G; Baleydier A; Ravaud P; Dougados M
    Ann Rheum Dis; 2010 Feb; 69(2):424-7. PubMed ID: 19740900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Acceptance and understandability of various methods of health valuations for the chronically ill: willingness to pay, visual analogue scale and rating scale].
    Meder M; Farin E
    Gesundheitswesen; 2009 Nov; 71(11):e62-71. PubMed ID: 20094981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of willingness to pay for implantable cardioverter-defibrillator therapy.
    Nowakowska D; Guertin JR; Liu A; Abrahamowicz M; Lelorier J; Lespérance F; Brophy JM; Rinfret S
    Am J Cardiol; 2011 Feb; 107(3):423-7. PubMed ID: 21257009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade).
    Kobelt G; Andlin-Sobocki P; Brophy S; Jönsson L; Calin A; Braun J
    Rheumatology (Oxford); 2004 Sep; 43(9):1158-66. PubMed ID: 15226514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to pay for kidney transplantation among chronic kidney disease patients in Ghana.
    Boima V; Agyabeng K; Ganu V; Dey D; Yorke E; Amissah-Arthur MB; Wilson AA; Yawson AE; Mate-Kole CC; Nonvignon J
    PLoS One; 2020; 15(12):e0244437. PubMed ID: 33378327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus development on eligibility of government subsidisation of biologic disease modifying anti-rheumatic agents for treatment of ankylosing spondylitis: The Singapore experience.
    Cheung PP; Lahiri M; Teng GG; Lui NL; Chia FL; Koh DR; Koh WH; Ng SC; Suresh E; Leong KP; Lim AYN; Thumboo J; Lau TC; Leong KH
    Int J Rheum Dis; 2017 Oct; 20(10):1517-1526. PubMed ID: 26177789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of Patients' Willingness to Pay for a Cure of Chronic Obstructive Pulmonary Disease in Taiwan.
    Chen YT; Ying YH; Chang K; Hsieh YH
    Int J Environ Res Public Health; 2016 Mar; 13(3):. PubMed ID: 26938547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-benefit of cholinesterase inhibitors in mild to moderate dementia: a willingness-to-pay approach.
    Wu G; Lanctôt KL; Herrmann N; Moosa S; Oh PI
    CNS Drugs; 2003; 17(14):1045-57. PubMed ID: 14594444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.